News2 mins ago
ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023
SHENZHEN, China, June 6, 2023 /PRNewswire/ — ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) and MVR-T3011 IV...
